JP2012517017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517017A5 JP2012517017A5 JP2011549163A JP2011549163A JP2012517017A5 JP 2012517017 A5 JP2012517017 A5 JP 2012517017A5 JP 2011549163 A JP2011549163 A JP 2011549163A JP 2011549163 A JP2011549163 A JP 2011549163A JP 2012517017 A5 JP2012517017 A5 JP 2012517017A5
- Authority
- JP
- Japan
- Prior art keywords
- indication
- capsid protein
- subject
- biological sample
- variant jcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 claims description 46
- 108090000565 Capsid Proteins Proteins 0.000 claims description 43
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 43
- 239000012472 biological sample Substances 0.000 claims description 31
- 239000000523 sample Substances 0.000 claims description 20
- 125000000539 amino acid group Chemical class 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 9
- 230000001506 immunosuppresive effect Effects 0.000 claims description 8
- 230000035945 sensitivity Effects 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15031009P | 2009-02-05 | 2009-02-05 | |
| US61/150,310 | 2009-02-05 | ||
| PCT/US2010/000342 WO2010090757A1 (en) | 2009-02-05 | 2010-02-05 | Methods for the detection of jc polyoma virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012517017A JP2012517017A (ja) | 2012-07-26 |
| JP2012517017A5 true JP2012517017A5 (enExample) | 2013-03-14 |
Family
ID=42542341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549163A Ceased JP2012517017A (ja) | 2009-02-05 | 2010-02-05 | Ｊｃポリオーマウイルスの検出のための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130101985A9 (enExample) |
| EP (1) | EP2394163B1 (enExample) |
| JP (1) | JP2012517017A (enExample) |
| CN (2) | CN104316696A (enExample) |
| AU (1) | AU2010210979B2 (enExample) |
| BR (1) | BRPI1016273A2 (enExample) |
| CA (1) | CA2751364C (enExample) |
| ES (1) | ES2842425T3 (enExample) |
| NZ (1) | NZ594973A (enExample) |
| SG (2) | SG173201A1 (enExample) |
| WO (1) | WO2010090757A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1988921A4 (en) | 2006-02-28 | 2010-02-10 | Elan Pharm Inc | METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB |
| EP3360900A1 (en) | 2006-03-03 | 2018-08-15 | Biogen MA Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| JP2012517017A (ja) | 2009-02-05 | 2012-07-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｊｃポリオーマウイルスの検出のための方法 |
| US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
| AU2011203815B2 (en) | 2010-01-11 | 2015-11-26 | Biogen Ma Inc. | Assay for JC virus antibodies |
| WO2012166971A2 (en) | 2011-05-31 | 2012-12-06 | Biogen Idec Ma Inc. | Method of assessing risk of pml |
| LT2734544T (lt) | 2011-07-18 | 2021-04-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Su poliomavirusu susijusios patologijos slopinimo metodai ir kompozicijos |
| EP2548567A1 (en) | 2011-07-22 | 2013-01-23 | Universitätsklinikum Hamburg-Eppendorf | Polyoma virus JC peptides and proteins in vaccination and diagnostic applications |
| EP2636746A1 (en) | 2012-03-06 | 2013-09-11 | Life Science Inkubator | A novel drug delivery system based on JCV-VLP |
| DK2828292T3 (da) | 2012-03-20 | 2019-01-02 | Biogen Ma Inc | Jcv-neutraliserende antistoffer |
| PT2828284T (pt) | 2012-03-20 | 2019-06-17 | Biogen Ma Inc | Jcv neutralizando anticorpos |
| WO2013192100A1 (en) | 2012-06-18 | 2013-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods and compositions for detecting jc virus |
| US9771413B2 (en) | 2012-12-31 | 2017-09-26 | Neurimmune Holding Ag | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
| EP2774991B1 (en) * | 2013-03-06 | 2017-12-06 | Life Science Inkubator Betriebs GmbH & Co. KG | Drug delivery system for use in the treatment or diagnosis of neurological disorders |
| WO2014145243A2 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | High resolution melting analysis assay for the detection of viral dna |
| EP3004334A4 (en) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | METHOD FOR ASSESSING A PML RISK |
| US9931393B2 (en) | 2013-12-20 | 2018-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic JC polyomavirus compositions and methods of use |
| US20200197544A1 (en) * | 2017-04-26 | 2020-06-25 | Biogen Ma Inc. | Jcv imaging methods and compositions |
| CN112442553A (zh) * | 2020-10-27 | 2021-03-05 | 深圳市罗湖区人民医院 | 一种用于JCPyV检测与分型的试剂盒及方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3767755B2 (ja) * | 1995-06-23 | 2006-04-19 | エーザイ株式会社 | 抗ｊｃウイルス抗体 |
| DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| JP2000506378A (ja) | 1996-01-26 | 2000-05-30 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア． | アナライトの直接的発色検出用のポリマーフィルム、アッセイおよび方法 |
| DE10131145B4 (de) | 2001-06-28 | 2005-07-14 | Innovent E.V. | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen |
| JP4840792B2 (ja) | 2001-11-22 | 2011-12-21 | 独立行政法人科学技術振興機構 | ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療 |
| US20080131928A1 (en) | 2004-07-01 | 2008-06-05 | Hiroshi Handa | Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions |
| JP4757103B2 (ja) | 2005-06-13 | 2011-08-24 | 学校法人関西文理総合学園 | 試料中のウイルスを検出する方法およびシステム |
| US7468186B2 (en) | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
| EP1951888B1 (en) | 2005-11-09 | 2012-09-05 | PrimeraDx, Inc. | Multiplexed quantitative detection of pathogens |
| US7769230B2 (en) * | 2006-11-30 | 2010-08-03 | Eastman Kodak Company | Producing low resolution images |
| WO2008077511A1 (en) | 2006-12-22 | 2008-07-03 | Karolinska Institutet Innovations Ab | Human polyomavirus and methods of diagnosis and treatment |
| JP2008249433A (ja) | 2007-03-29 | 2008-10-16 | Kansai Bunri Sogo Gakuen | 被験物質に対するプローブの結合親和性を測定する方法及びその利用 |
| WO2009100351A2 (en) | 2008-02-08 | 2009-08-13 | Alnylam Pharmaceuticals, Inc. | Delivery of rnai constructs to oligodendrocytes |
| JP2012517017A (ja) | 2009-02-05 | 2012-07-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｊｃポリオーマウイルスの検出のための方法 |
| BR112014002126A2 (pt) | 2011-07-29 | 2017-02-21 | Biogen Idec Inc | ensaio para detecção de dna do vírus jc |
| AR095089A1 (es) | 2013-01-30 | 2015-09-30 | Biogen Idec Inc | Ensayo de detección de adn de virus jc |
-
2010
- 2010-02-05 JP JP2011549163A patent/JP2012517017A/ja not_active Ceased
- 2010-02-05 ES ES10738871T patent/ES2842425T3/es active Active
- 2010-02-05 CN CN201410478514.8A patent/CN104316696A/zh active Pending
- 2010-02-05 EP EP10738871.2A patent/EP2394163B1/en active Active
- 2010-02-05 BR BRPI1016273-9A patent/BRPI1016273A2/pt not_active Application Discontinuation
- 2010-02-05 SG SG2011055514A patent/SG173201A1/en unknown
- 2010-02-05 CA CA2751364A patent/CA2751364C/en active Active
- 2010-02-05 SG SG2014009120A patent/SG2014009120A/en unknown
- 2010-02-05 US US13/147,484 patent/US20130101985A9/en not_active Abandoned
- 2010-02-05 WO PCT/US2010/000342 patent/WO2010090757A1/en not_active Ceased
- 2010-02-05 CN CN201080014394.6A patent/CN102369436B/zh active Active
- 2010-02-05 AU AU2010210979A patent/AU2010210979B2/en active Active
- 2010-02-05 NZ NZ594973A patent/NZ594973A/xx unknown
-
2015
- 2015-01-22 US US14/603,002 patent/US9696307B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517017A5 (enExample) | ||
| Kinloch et al. | In situ humoral immunity to vimentin in HLA-DRB1* 03+ patients with pulmonary sarcoidosis | |
| Vodnik et al. | Phage display: selecting straws instead of a needle from a haystack | |
| Furmaga et al. | BK polyomavirus—biology, genomic variation and diagnosis | |
| DK1668368T3 (da) | Detektion af histon-modifikation i cellefrie nukleosomer | |
| Fu et al. | The utility of specific antibodies against SARS-CoV-2 in laboratory diagnosis | |
| Aulakh et al. | The promise of circulating tumor DNA in head and neck cancer | |
| EA201171046A1 (ru) | Зонды и праймеры для детектирования вируса чикунгуньи | |
| JO3812B1 (ar) | أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1) | |
| Dahlke et al. | Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series | |
| DK2132339T3 (da) | Fremgangsmåde til detektering af en analyt i en biologisk matrix | |
| Liang et al. | Novel biosensor platforms for the detection of coronavirus infection and severe acute respiratory syndrome coronavirus 2 | |
| Peker et al. | Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis | |
| JP2017522555A5 (enExample) | ||
| Trier et al. | Epitope specificity of anti-citrullinated protein antibodies | |
| Hwang et al. | Identification of high affinity peptides for capturing norovirus capsid proteins | |
| Zhang et al. | Proteome-wide analysis of differentially-expressed SARS-CoV-2 antibodies in early COVID-19 infection | |
| CN101156068A (zh) | 检测错折叠蛋白和朊病毒的方法 | |
| Mendoza et al. | Polyomaviruses After Allogeneic Hematopoietic Stem Cell Transplantation | |
| Malsagova et al. | Ultrasensitive nanowire-based detection of HCVcoreAg in the serum using a microwave generator | |
| WO2007001737A3 (en) | Methods and compositions for detecting herpes simplex virus type 2 | |
| Ishida et al. | Selective detection of airborne asbestos fibers using protein-based fluorescent probes | |
| WO2008070570A3 (en) | Positive selection of serum proteins for proteomic analysis | |
| Andersen et al. | Nanotrap particles improve nanopore sequencing of SARS-CoV-2 and other respiratory viruses | |
| Fiedler et al. | In vitro measurements of protein–protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum |